Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Second Magnetic Resonance Guided Focused Ultrasound Thalamotomy for Essential Tremor

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04720469
Recruitment Status : Recruiting
First Posted : January 22, 2021
Last Update Posted : January 22, 2021
Sponsor:
Information provided by (Responsible Party):
Sunnybrook Health Sciences Centre

Brief Summary:

This study will be a single-centre, prospective, single-arm, open-label, 12-week pilot trial assessing the safety and preliminary efficacy of a second MR-guided focused ultrasound (MRgFUS) thalamotomy on the naïve brain hemisphere after 48 weeks or more of the first MRgFUS thalamotomy in patients with medication-refractory ET.

This study will be conducted at the Focused Ultrasound Centre of Excellence at Sunnybrook Health Sciences Centre/University of Toronto.


Condition or disease Intervention/treatment Phase
Essential Tremor Device: MRgFUS thalamotomy Not Applicable

Detailed Description:
Patients who are medication-refractory for ET often require a surgical option to relieve symptoms of ET and improve quality of life. To-date, unilateral MRgFUS has been beneficial in providing patients with some of relief from tremor. However, tasks that require two hands remain a challenge for many patients. Historical risks of bilateral treatment have been an impediment to complete tremor relief. The introduction of MRI and current stereotactic methodologies has significantly reduced the probability of non-target tissue injury. In this study, a second MRgFUS thalamotomy will be performed in a cohort of patients who have already successfully undergone unilateral MRgFUS treatment. Tremor severity, speech, balance, gait, and cognition will be assessed during baseline and follow up visits.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 12 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Intervention Model Description: Single-arm, pre/post designl study
Masking: None (Open Label)
Masking Description: This study is open label. CRST rating will be performed by a trained neurologist who will be blinded to whether the CRST data were collected pre- or post- treatment.
Primary Purpose: Treatment
Official Title: A Safety Pilot Clinical Trial of a Second Magnetic Resonance Guided Focused Ultrasound (MRgFUS) Thalamotomy for the Management of Medication-refractory Essential Tremor
Actual Study Start Date : October 5, 2020
Estimated Primary Completion Date : October 31, 2022
Estimated Study Completion Date : October 31, 2023

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Tremor Ultrasound

Arm Intervention/treatment
Experimental: Patients with bilateral essential tremor who have undergone one MRgFUS thalamotomy
Patients with bilateral essential tremor who have undergone one MRgFUS thalamotomy
Device: MRgFUS thalamotomy
Ablation of untreated thalamus using focused ultrasound to abate tremor.
Other Name: ExAblate Neuro




Primary Outcome Measures :
  1. Incidence at week 12 of new onset or significant worsening of: ataxic gait; speech impairment; cognitive impairment; contralateral weakness; patient-reported disabling sensory loss; Severe AEs related to the MRgFUS procedure. [ Time Frame: 12 weeks ]
    This composite outcome will be measured by the Scale for the Assessment and Rating of Ataxia (SARA) scale, neuropsychology battery, neurological examination and AE reports.


Secondary Outcome Measures :
  1. Change in the tremor score (Part A and B) from baseline to 12 weeks after MRgFUS thalamotomy, adjusted for baseline scores. [ Time Frame: 12 weeks ]
    This CRST subscore will be measured on the treated side.

  2. Change in QUEST global score and EQ-5D from baseline to 12 weeks after MRgFUS, adjusted for baseline scores. [ Time Frame: 12 weeks ]
    QUEST (Quality of Life in Essential Tremor) is a disease-specific quality of life scale.


Other Outcome Measures:
  1. Change in speech intelligibility and speaking rate from baseline to 12 weeks after MRgFUS thalamotomy, adjusted for baseline scores. [ Time Frame: 12 weeks ]
    Speech intelligibility is measured as the percentage of intelligible words and speaking rate is measured as words per minute.

  2. Change in the subscores of neuropsychological tests and self-reported questionnaires from baseline to 12 weeks after MRgFUS thalamotomy. [ Time Frame: 12 weeks ]
    Alternative versions of the neuropsychological tests and self-reported questionnaires of cognitive function will be used in the baseline and week 12 visit to account for a learning effect.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   22 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Individuals aged 22 years or older;
  2. Subjects who are able and willing to give consent and able to attend all study visits and MRgFUS procedure, understanding the associated risks, benefits, and alternative treatments;
  3. Diagnosis of ET as confirmed from clinical history and examination by a neurologist or neurosurgeon and unilateral MRgFUS thalamotomy at least 48 weeks prior;
  4. On a stable dose of medication for tremor for at least 4 weeks;
  5. Medication-refractory criterion: tremor refractory to adequate trials of at least two medications, one of which should be a first line therapy of either propranolol or primidone. An adequate medication trial is defined as a therapeutic dose of each medication or the development of side effects as the medication dose is titrated;
  6. Moderate-severe tremor severity criteria in the untreated hand: Despite medical treatment, untreated hand score of ≥2 points in the postural or intention component of the item 5 or 6 in the Part A of CRST, AND untreated hand score of ≥2 points in any one of the items 12-15 of the Part B of CRST;
  7. Disability criterion: ≥2 points in any one of the Part C items 17-23 as measured by the CRST;
  8. Able to communicate sensations during the MRgFUS treatment and to press the device STOP button.

Exclusion Criteria:

  1. Patients with standard contraindications for MR imaging such as non-MRI compatible implanted metallic devices including cardiac pacemakers, size limitations, etc;
  2. Women who are pregnant;
  3. Gait subscore ≥2 points in the SARA scale;
  4. Speech subscore ≥2 points in the SARA scale;
  5. Patients with advanced kidney disease (with estimated glomerular filtration rate <30 mL/min/1.73m2) or on dialysis;
  6. Patients with unstable cardiac status or severe hypertension including:

    1. Documented myocardial infarction within six months of enrollment
    2. Unstable angina on medication
    3. Unstable or worsening congestive heart failure
    4. Left ventricular ejection fraction below the lower limit of normal
    5. History of a hemodynamically unstable cardiac arrhythmia
    6. Cardiac pacemaker
    7. Severe hypertension (diastolic BP > 100 on medication);
  7. Patients exhibiting any behaviour(s) or clinical assessment consistent with ethanol or substance abuse;
  8. Patients with history of abnormal bleeding, hemorrhage, and/or coagulopathy defined as abnormal coagulation profile (platelet < 100,00/μl), PT (>14 sec) or PTT (>36 sec), and INR > 1.3;
  9. Receiving anticoagulant (e.g. warfarin) or antiplatelet (e.g. aspirin) therapy within one week of focused ultrasound procedure or drugs known to increase risk or hemorrhage (e.g. Avastin) within one month of focused ultrasound procedure;
  10. Ischemic or hemorrhagic stroke within 6 months;
  11. Patients with brain tumors;
  12. Individuals who are not able or unwilling to tolerate the required prolonged stationary position during treatment (approximately 2-3 hours);
  13. Patients who are currently participating in another clinical investigation with an active treatment arm;
  14. Patients who have had deep brain stimulation (DBS) or a prior stereotactic ablation of the basal ganglia with GKRS or radiofrequency;
  15. Patients who have been administered botulinum toxins into the arm for 5 months prior to baseline.
  16. Evidence of clinically important movement disorder, such as chorea, dystonia, or parkinsonism. Anyone with the presence of parkinsonian features including bradykinesia, rigidity, or postural instability will be excluded. Subjects who exhibit only mild resting tremor but no other symptoms or signs of Parkinson's disease may be included.
  17. Symptoms and signs of increased intracranial pressure (e.g. headache, nausea, vomiting, lethargy, and papilledema);
  18. Untreated, uncontrolled sleep apnea;
  19. Presence of any other neurodegenerative disease like multisystem atrophy, progressive supranuclear palsy, dementia with Lewy bodies, and Alzheimer's disease;
  20. Mild cognitive impairment with impairment in the domain of language as determined by screening neuropsychological battery and judged by study neuropsychologist;
  21. A known diagnosis of dementia of any cause;
  22. Uncontrolled major psychiatric disorder or suicidal ideation. Patients with psychiatric disorders identified on initial screening can be treated for these conditions before MRgFUS treatment and enrolled if deemed psychiatrically stable for at least three months before study entry. Any presence of psychosis will be excluded;
  23. Any illness that in the investigator's opinion preclude participation in this study;
  24. Patients with a history of seizures within the past year.
  25. Inability to generate a thermal thalamic lesion during the first MRgFUS procedure;
  26. Poor tolerance to the first MRgFUS procedure;
  27. Severe adverse event or moderate-severe adverse event related to the MRgFUS procedure or thalamotomy, such as clinically significant and permanent speech, language, sensory, motor or gait dysfunction.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04720469


Contacts
Layout table for location contacts
Contact: Nadia Scantlebury, PhD 416-480-6100 ext 4390 nadia.scantlebury@sunnybrook.ca

Locations
Layout table for location information
Canada, Ontario
Sunnybrook Health Sciences Centre Recruiting
Toronto, Ontario, Canada, M4N 3M5
Contact: Nadia Scantlebury, PhD    416-480-6100 ext 4390    nadia.scantlebury@sunnybrook.ca   
Sponsors and Collaborators
Sunnybrook Health Sciences Centre
Investigators
Layout table for investigator information
Principal Investigator: Agessandro Abrahao, MD, MSc Sunnybrook Health Sciences Centre
Additional Information:
Layout table for additonal information
Responsible Party: Sunnybrook Health Sciences Centre
ClinicalTrials.gov Identifier: NCT04720469    
Other Study ID Numbers: 3341
First Posted: January 22, 2021    Key Record Dates
Last Update Posted: January 22, 2021
Last Verified: January 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Plan Description: Individual participant data can be made available by request and approval of the Sunnybrook REB and study PI.

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Tremor
Essential Tremor
Dyskinesias
Neurologic Manifestations
Nervous System Diseases
Movement Disorders
Central Nervous System Diseases